ArticleFunction (Oxford, England)2025
Canagliflozin Inhibits Electrogenic Na+ Transport in Mouse Cortical Collecting Duct Cells.
Article in Function (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) exhibit cardiorenal protective effects that likely involve mechanisms aside from SGLT2 inhibition. Still, many details surrounding these clinically important pleiotropic effects remain unclear. We previously showed that several SGLT2-independent proximal tubular transport functions are inhibited by canagliflozin, but not empagliflozin. Here, we demonstrate a canagliflozin-specific reduction in Sgk1 abundance in both opossum kidney proximal tubule and mouse cortical collecting duct (mCCDcl1) cells, pointing to a possible underlying mechanism. Given the role of Sgk1 in the distal nephron, we hypothesized that canagliflozin would also inhibit epithelial Na+ channel (ENaC)-dependent Na+ transport. Canagliflozin inhibited ENaC-dependent Na+ transport (amiloride-sensitive short circuit current; ISC) in mCCDcl1 cells while empagliflozin had no effect. Selective membrane permeabilization revealed canagliflozin-induced inhibition of both apical conductance through ENaC and basolateral transport via the Na+/K+ ATPase. These effects were mimicked by the selective Sgk1 inhibitor, GSK650394. Surface labeling studies demonstrated reduced membrane localization of ENaC, but not Na+/K+ ATPase subunits, consistent with a mechanism involving Sgk1. Canagliflozin reduced ISC in the presence and absence of rotenone, suggesting inhibition occurs independently of effects on mitochondrial complex I, another known target of canagliflozin. ENaC activity in mouse distal colon was also inhibited by canagliflozin, confirming these effects in native tissue. We identify Na+ transport through ENaC and the Na+/K+ ATPase as novel targets of inhibition by canagliflozin, with Sgk1 as a likely upstream mechanistic component. Canagliflozin-specific effects on transport mediated via this mechanism may contribute to non-class effects of this drug observed clinically.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.